|
|
 |
|
Viewing report
|
|
|
|
Wyeth: Performance, Products, Pipeline and Potential
Espicom Business Intelligence Ltd, March 2008, Pages: 152
Wyeth is one of the world’s largest research-based pharmaceutical and healthcare products companies and is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, biotechnology products, vaccines, non-prescription medicines and animal health products. Wyeth currently operates in over 145 countries worldwide.
Fiscal 2007 was a strong year for Wyeth, with the company achieving record levels of sales and income. In terms of pharmaceuticals sales, Wyeth maintained its place in the top ten research-based pharmaceutical companies worldwide. This success was based on strong growth of its biotechnology products Enbrel and Prevnar, the launch of Torisel and Lybrel, and the company's continued expansion into China, the Middle East and Latin America. Furthermore, Wyeth reported successful cost-management efforts through the efficient implementation of its ''Project Springboard'' scheme.
Wyeth’s growth is based on a strong foundation of products, which includes Effexor, Protonix, Enbrel, Prevnar, Zosyn, and the Premarin franchise. Productivity, coupled with significant investment in facilities (for example, Wyeth’s US$2 billion biotech manufacturing site in Grange Castle, Ireland) allowed the company to achieve record levels of production for its lead vaccine, Prevnar, and accommodation of the increasing demand for Enbrel, which is fast becoming one of the world’s leading rheumatoid arthritis treatments.
However, sustained growth is threatened by the loss of patent protection for several products including Effexor (Wyeth’s top-seller), Prevnar and Zosyn. Wyeth has assembled a strong pipeline, which may yield compounds to follow in the footsteps of these leading products. Desvenlafaxine and the 13-valent pneumococcal vaccine have the potential to succeed Effexor and Prevnar respectively, whilst the recently-launched Tygacil is anticipated to provide a boost to the Anti-infective therapeutic area, whose sales were set to suffer with the loss of Zosyn’s market protection.
Customers who bought this item also bought
Pfizer: Pipeline, Products, Performance, Potential
Human Vaccines - Global Strategic Business Report
Strategic Overview of the Infectious Disease Vaccine
Pneumococcal Infections - Pipeline Assessment and Market Forecasts to 2017
Global Biopharma Outlook 2011
Women's Health Review and Outlook 2011
The Future of Global Vaccines - Market Forecasts to 2016, Stockpile Analysis, Competitive Benchmarking and Pipeline Analysis
World Vaccines Market 2008-2013: Future Forecast, Critical Trends and Developments
Infectious Diseases Vaccine Market Overview
Next-Generation Infectious Disease Vaccines: Novel Technologies and Opportunities
|
|
|
|
